0
0
0
Hatch-Waxman Improvement Act of 2022
12/29/2022, 5:33 PM
Congressional Summary of S 4378
Hatch-Waxman Improvement Act of 2022
This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).
Read the Full Bill
Current Status of Bill S 4378
Bill S 4378 is currently in the status of Bill Introduced since June 13, 2022. Bill S 4378 was introduced during Congress 117 and was introduced to the Senate on June 13, 2022. Bill S 4378's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of June 13, 2022
Bipartisan Support of Bill S 4378
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
0Democrat Cosponsors
0Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 4378
Primary Policy Focus
HealthAlternate Title(s) of Bill S 4378
Hatch-Waxman Improvement Act of 2022
Hatch-Waxman Improvement Act of 2022
A bill to reauthorize a provision of the Federal Food, Drug, and Cosmetic Act pertaining to drugs containing single enantiomers.
Comments
Sponsors and Cosponsors of S 4378
Latest Bills
Stop CHEATERS Act
Bill HR 9736July 30, 2026
Patients First Act of 2026
Bill HR 9693July 30, 2026
National Defense Authorization Act for Fiscal Year 2027
Bill S 4784July 30, 2026
Health and Location Data Protection Act of 2026
Bill S 4946July 30, 2026
POPCaP Act of 2026
Bill S 4993July 30, 2026
Protecting Students from Worthless Degrees Act
Bill S 5021July 30, 2026
Protecting Indian Water Rights Settlements Act of 2026
Bill S 4890July 30, 2026
Washington’s Trail—1753 National Historic Trail Feasibility Study Act of 2026
Bill S 4538July 30, 2026
Bay Area Ridge National Scenic Trail Feasibility Study Act
Bill S 3720July 30, 2026
Geese House Site Conveyance Act
Bill S 4399July 30, 2026
FDASLA Act of 2022
Bill S 4348December 29, 2022